A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
See Screening Protocol LUNGMAP
S1900A is permanently closed to new accrual effective, February 1, 2021.
